The U.S. Federal Trade Commission is looking into how big pharmacy benefit managers like OptumRx and Prime Therapeutics affect pricing and patients' access to prescription drugs at a time when costs of some medicines, even older ones like insulin, have skyrocketed, the agency said Tuesday. As part of the probe, the FTC is sending demands for information to CVS Health Corp.'s Caremark, Humana Inc., Cigna Corp.'s Express Scripts and UnitedHealth Group's OptumRx, among others. You've read your complimentary articles for this time period.
  Subscribe now.
  Already a subscriber? Log in here.